EMEA-001071-PIP03-14-M01 - paediatric investigation plan

Certolizumab pegol

Key facts

• Invented name:
  Cimzia
• Active Substance:
  Certolizumab pegol
• Therapeutic area:
  Dermatology
• Decision number:
  P/0397/2018
• PIP number:
  EMEA-001071-PIP03-14-M01
• Pharmaceutical form(s):
  Solution for injection
• Condition(s) / indication(s):
  Treatment of psoriasis
• Route(s) of administration:
  Subcutaneous use
• Decision type:
  W: decision granting a waiver in all age groups for all conditions or indications
• Decision date:
  07/12/2018

Decision

P/0397/2018: EMA of 7 December 2018 on the acceptance of a modification of an agreed paediatric investigation plan for certolizumab pegol (Cimzia), (EMEA-001071-PIP03-14-M01)

AdoptedReference Number: EMA/796523/2018